The Role of SGLT2 Inhibitors in Cardiovascular Risk Reduction in Type 2 Diabetes
1Dr Furqan Shahjehan, 2Dr Qurat-Ul-Ain Bukhari 3Umar Shah, 4Naznin tabbasum, 5Qaiser ikhlaq, 6Haroon raja
1Niazi medical and dental college Sargodha
2Altamash Institute of Dental Medicine
3PIMS, Islamabad,
4Service Hospital, Faisalabad
5UHS, Lahore
6Gangaram Hospital, Lahore
Vol: 16/03
Received: January 25, 2026 Accepted: March 02, 2026 Published: July 06, 2026
Abstract
Background: Sodium-glucose co-transporter 2 inhibitors, usually developed for glycemic control in type 2 diabetes mellitus, have illustrated remarkable cardiovascular benefits in specific clinical trials. Their mechanism of action broadened beyond glucose lowering, purposing the pleiotropic effects that may give to reduced cardio-vascular risk.Objective: To find out the effectiveness of SGLT2 inhibitors in reduction of cardiovascular events between patients with T2DM and highlight patterns at different cardiovascular results. Methods: A Backdated group analysis of published randomized controlled trials and real-world studies was held. Patients with T2DM receiving SGLT2 inhibitors were linked for changes in cardio-vascular results including major adverse cardio-vascular events, heart failure hospitalization, and cardio-vascular mortality. Results: SGLT2 inhibitors remarkably reduced the risk of HFH less than 30% and CV mortality at 20% contrasting to placebo. The effect on MACE was more modest but statistically remarkable. Subgroup analyses highlight consistent benefits across age, sex, and comorbidities. Conclusion: SGLT2 inhibitors consult robust cardio-vascular protection in patients with T2DM, specifically in reducing HFH and CV death. These findings give strength to their broader use in T2DM management with cardio-vascular risk. Keywords: Cardiovascular risk, heart strokes, mortality rate, inhibitors., SGLT2 inhibitors, cardio-vascular, patients, T2DM management